Resource centre

Save your spot for our next webinar featuring a customer case study from Ensysce Biosciences on April 19, 2023. Dr. Vanessa Zann, Senior Drug Development Consultant, will be joined by Lynn Kirkpatrick, CEO of Ensysce Biosciences for this special presentation.

Join experts from Quotient Sciences & Charles River for a webinar taking place on 18 May, "Integrated Strategies for Accelerating from Discovery to IND and Beyond: Charles River & Quotient Sciences Collaboration."

A core component of Quotient Sciences is our integrated capabilities in drug substance process research, development, and manufacturing. All are carried out at our state-of-the-art facility in Alnwick, UK.

In this report, the European Bioanalysis Forum shares the proposals for harmonized implementation of the ICH M10 guideline on bioanalytical method validation and study sample analysis from the ICH M10 workshop.

We are a leading provider of 14C-enabled drug development programs, successfully conducting over 350 human ADME and other radiolabeled programs to date. Learn about Synthesis-to-Clinic®.

The use of electrospraying as a means of drug loading into mesoporous silica particles for enhanced dissolution, presented at the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology 2022

Learn about drug substance and formulation considerations for improving downstream clinical outcomes. Access on demand.

A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes.

Safety, tolerability, and pharmacokinetics of the oligomer modulator anle138b: a first-in-human randomised, double-blind, placebo-controlled Phase 1 trial

Practical and operational considerations related to paediatric oral drug formulation: An industry survey.

Understanding the Absorption, Metabolism and Excretion of Masitinib in Healthy Male Subjects.

A Phase I Study of the Cancer-specific Vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response